These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 18184365)

  • 1. Motor impairment in Alzheimer's disease and transgenic Alzheimer's disease mouse models.
    Wirths O; Bayer TA
    Genes Brain Behav; 2008 Feb; 7 Suppl 1():1-5. PubMed ID: 18184365
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ultrasound with microbubbles improves memory, ameliorates pathology and modulates hippocampal proteomic changes in a triple transgenic mouse model of Alzheimer's disease.
    Shen Y; Hua L; Yeh CK; Shen L; Ying M; Zhang Z; Liu G; Li S; Chen S; Chen X; Yang X
    Theranostics; 2020; 10(25):11794-11819. PubMed ID: 33052247
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Do axonal defects in tau and amyloid precursor protein transgenic animals model axonopathy in Alzheimer's disease?
    Götz J; Ittner LM; Kins S
    J Neurochem; 2006 Aug; 98(4):993-1006. PubMed ID: 16787410
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of CX3CR1 and Fractalkine Chemokines in Amyloid Beta Clearance and p-Tau Accumulation in Alzheimer's Disease (AD) Rodent Models: Is Fractalkine a Systemic Biomarker for AD?
    Merino JJ; Muñetón-Gómez V; Alvárez MI; Toledano-Díaz A
    Curr Alzheimer Res; 2016; 13(4):403-12. PubMed ID: 26567742
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intensive 'Brain Training' Intervention Fails to Reduce Amyloid Pathologies or Cognitive Deficits in Transgenic Mouse Models of Alzheimer's Disease.
    Anderson M; Xu F; Ou-Yang MH; Davis J; Van Nostrand WE; Robinson JK
    J Alzheimers Dis; 2017; 55(3):1109-1121. PubMed ID: 27767989
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trem2 restrains the enhancement of tau accumulation and neurodegeneration by β-amyloid pathology.
    Lee SH; Meilandt WJ; Xie L; Gandham VD; Ngu H; Barck KH; Rezzonico MG; Imperio J; Lalehzadeh G; Huntley MA; Stark KL; Foreman O; Carano RAD; Friedman BA; Sheng M; Easton A; Bohlen CJ; Hansen DV
    Neuron; 2021 Apr; 109(8):1283-1301.e6. PubMed ID: 33675684
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overexpression of Ubiquilin-1 Alleviates Alzheimer's Disease-Caused Cognitive and Motor Deficits and Reduces Amyloid-β Accumulation in Mice.
    Adegoke OO; Qiao F; Liu Y; Longley K; Feng S; Wang H
    J Alzheimers Dis; 2017; 59(2):575-590. PubMed ID: 28598849
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular and functional signatures in a novel Alzheimer's disease mouse model assessed by quantitative proteomics.
    Kim DK; Park J; Han D; Yang J; Kim A; Woo J; Kim Y; Mook-Jung I
    Mol Neurodegener; 2018 Jan; 13(1):2. PubMed ID: 29338754
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A decade of modeling Alzheimer's disease in transgenic mice.
    McGowan E; Eriksen J; Hutton M
    Trends Genet; 2006 May; 22(5):281-9. PubMed ID: 16567017
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model.
    Roberson ED; Scearce-Levie K; Palop JJ; Yan F; Cheng IH; Wu T; Gerstein H; Yu GQ; Mucke L
    Science; 2007 May; 316(5825):750-4. PubMed ID: 17478722
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunotherapy to improve cognition and reduce pathological species in an Alzheimer's disease mouse model.
    Herline K; Prelli F; Mehta P; MacMurray C; Goñi F; Wisniewski T
    Alzheimers Res Ther; 2018 Jun; 10(1):54. PubMed ID: 29914551
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Motor function deficits in the 12 month-old female 5xFAD mouse model of Alzheimer's disease.
    O'Leary TP; Robertson A; Chipman PH; Rafuse VF; Brown RE
    Behav Brain Res; 2018 Jan; 337():256-263. PubMed ID: 28890389
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selenomethionine Mitigates Cognitive Decline by Targeting Both Tau Hyperphosphorylation and Autophagic Clearance in an Alzheimer's Disease Mouse Model.
    Zhang ZH; Wu QY; Zheng R; Chen C; Chen Y; Liu Q; Hoffmann PR; Ni JZ; Song GL
    J Neurosci; 2017 Mar; 37(9):2449-2462. PubMed ID: 28137967
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transgenic mouse models for Alzheimer's disease: the role of GSK-3B in combined amyloid and tau-pathology.
    Muyllaert D; Terwel D; Borghgraef P; Devijver H; Dewachter I; Van Leuven F
    Rev Neurol (Paris); 2006 Oct; 162(10):903-7. PubMed ID: 17028556
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cu, Fe, and Zn isotope ratios in murine Alzheimer's disease models suggest specific signatures of amyloidogenesis and tauopathy.
    Solovyev N; El-Khatib AH; Costas-Rodríguez M; Schwab K; Griffin E; Raab A; Platt B; Theuring F; Vogl J; Vanhaecke F
    J Biol Chem; 2021; 296():100292. PubMed ID: 33453282
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Spatial Memory Impairment is Associated with Intraneural Amyloid-β Immunoreactivity and Dysfunctional Arc Expression in the Hippocampal-CA3 Region of a Transgenic Mouse Model of Alzheimer's Disease.
    Morin JP; Cerón-Solano G; Velázquez-Campos G; Pacheco-López G; Bermúdez-Rattoni F; Díaz-Cintra S
    J Alzheimers Dis; 2016; 51(1):69-79. PubMed ID: 26836189
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cognitive and non-cognitive behaviors in the triple transgenic mouse model of Alzheimer's disease expressing mutated APP, PS1, and Mapt (3xTg-AD).
    Filali M; Lalonde R; Theriault P; Julien C; Calon F; Planel E
    Behav Brain Res; 2012 Oct; 234(2):334-42. PubMed ID: 22796601
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Soluble Conformers of Aβ and Tau Alter Selective Proteins Governing Axonal Transport.
    Sherman MA; LaCroix M; Amar F; Larson ME; Forster C; Aguzzi A; Bennett DA; Ramsden M; Lesné SE
    J Neurosci; 2016 Sep; 36(37):9647-58. PubMed ID: 27629715
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alzheimer's Disease Animal Models: Elucidation of Biomarkers and Therapeutic Approaches for Cognitive Impairment.
    Nakai T; Yamada K; Mizoguchi H
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34074018
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Amyloid precursor protein reduction enhances the formation of neurofibrillary tangles in a mutant tau transgenic mouse model.
    Vanden Dries V; Stygelbout V; Pierrot N; Yilmaz Z; Suain V; De Decker R; Buée L; Octave JN; Brion JP; Leroy K
    Neurobiol Aging; 2017 Jul; 55():202-212. PubMed ID: 28464981
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.